Searchable abstracts of presentations at key conferences on calcified tissues

ba0006p004 | (1) | ICCBH2017

Bone mass tracks into teenage years

Ronne Maria , Heideman Malene , Schou Anders , Laursen Jens Ole , Wedderkopp Niels , Husby Steffen , Molgaard Christian

Objectives: Bone mass development in childhood and adolescence is crucial for peak bone mass (PBM) and low PBM may lead to osteoporosis later in life. The stability of bone mineral status through childhood and adolescence is known as tracking. The objective of this study is to determine the degree of tracking according to bone mass from pre-puberty into puberty in healthy Danish children.Methods: 190 healthy Danish children (97 boys) with mean age 9.25 y...

ba0007oc24 | (1) | ICCBH2019

TA-46, a recombinant soluble FGFR3 receptor for the treatment of achondroplasia, is safe and well-tolerated in healthy volunteers

Collins Samuel , Greig Gerard , Porter Richard , Stavenhagen Jeff , Santarelli Luca , Meyer Christian

Objectives: To assess the safety, tolerability and pharmacokinetic (PK) profile of single and multiple doses of TA-46 administered subcutaneously to healthy volunteers.Methods: This was a double-blind, randomized, placebo-controlled trial in a total of 72 subjects. Cohorts of 8 subjects were randomised to receive either TA-46 or placebo in a 3:1 ratio in single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. SAD doses were 0.3, 1, 3, 10 a...

ba0001oc2.2 | Bone quality and fracture repair - animal models | ECTS2013

Intermittent human parathyroid hormone (1–84) treatment improves bone mass and bone defect healing in rats with type 2 diabetes mellitus

Hamann Christine , Picke Ann-Kristin , Rauner Martina , Bernhardt Ricardo , Campbell Graeme , Gluer Claus-Christian , Hofbauer Lorenz C

The pathogenesis of skeletal fragility in diabetes mellitus is poorly defined and efficient therapies are limited. Zucker diabetic fatty (ZDF) rats with type 2 diabetes mellitus display low bone mass and delayed bone defect healing. We tested whether intermittent treatment with human parathyroid hormone 1–84 (PTH) increases bone mass and bone defect regeneration in diabetic rats.A subcritical gap defect was created at the femur of 10 weeks old diabe...

ba0001pp40 | Bone biomechanics and quality | ECTS2013

Prediction of vertebral body stiffness in patients with multiple myeloma using qCT-based finite element models

Campbell Graeme , Graeff Christian , Giravent Sarah , Thomsen Felix , Pena Jaime , Wulff A , Gunther A , Gluer Claus C , Borggrefe Jan

Multiple myeloma (MM) is associated with lytic bone destruction leading to high fracture incidence in the vertebrae. Accurate assessment of fracture risk is required for physicians to determine the necessity for surgery. This risk is currently determined by examining lesion size or number; however, this method does not consider the biomechanical attributes of the bone. Finite element (FE) modelling can simulate mechanical loading on vertebral bodies, and estimate mechanical in...

ba0001pp453 | Osteoporosis: treatment | ECTS2013

Factors influencing levels of bone resorption during denosumab dosing

Eastell Richard , Siris Ethel , Roux Christian , Black Dennis M. , Franchimont Nathalie , Jang Graham , Daizadeh Nadia , Wagman Rachel B. , Austin Matt

Denosumab treatment is associated with low fracture incidence, sustained BMD increases, and reduced sCTX. The decrease in median sCTX is at the quantifiable limit (0.049 ng/ml) one month post-dose, remains low, and attenuates at the end of the 6-month dosing interval. Using 7 years of data from the FREEDOM study and its extension, we characterized changes in sCTX over time and the influencing factors. In the bone turnover marker and pharmacokinetic substudies, serum was collec...

ba0003pp18 | Bone biomechanics and quality | ECTS2014

Influence of PTH treatment on the bone tissue mechanics of rats with type 2 diabetes mellitus using mechanical tests and finite element modelling

Campbell Graeme , Hamann Christine , Picke Ann-Kristin , Rauner Martina , Huber Gerd , Morlock Michael , Hofbauer Lorenz , Gluer Claus-Christian

Diabetes mellitus results in increased skeletal fragility through reduced bone mineral density and altered collagen structure. How these changes affect bone mechanics at the tissue level remains largely unclear. Anti-osteoporosis medications improve bone mass, but whether they can fully restore tissue strength in diabetic bone, where collagen quality is compromised, has not been fully elucidated. The objective of this study was to determine the effect of type 2 diabetes mellit...

ba0003pp38 | Bone development/growth and fracture repair | ECTS2014

Development and characterization of novel biodegradable scaffold materials

Fowler Tristan , Kampleitner Carina , Poocza Leander , Markus Andrea , Dullin Christian , Hildebrand Gerhard , Alves Frauke , Liefeith Klaus , Hoffmann Oskar

The development of optimally performing biomaterials mimicking the natural physiological processes underlying bone repair is essential for non-healing large bone lesions. We sought to develop scaffolds that fill the lesions and improve bone healing. We tested three scaffolds comprised of varying percentages of lactide (LA), caprolactone (CL), and methacrylate produced by two-photon photopolymerization; LCM 3 (8:2; 85%), 4 (9:1; 90%), and 6 (9:1; 40%). We hypothesized that the ...

ba0003pp74 | Bone development/growth and fracture repair | ECTS2014

Bone turnover and FGF-23 levels in vitamin D-deficient critically ill patients with and without acute kidney injury

Schnedl Christian , Bisping Egbert , Zajic Paul , Dimai Hans Peter , Wagner Doris , Pieber Thomas R , Fahrleitner-Pammer Astrid , Amrein Karin

Introduction: Elevated FGF-23 serum levels are induced by hyperphosphatemia and are linked to poor skeletal mineralization and adverse outcomes including vascular calcification and mortality. Recently, it was shown that FGF-23 levels are substantially elevated in acute kidney injury (AKI), and that higher levels in AKI are associated with a greater risk of adverse outcomes.Methods: In 25 vitamin D deficient (25(OH)D <20 ng/ml) critically ill adults w...

ba0003pp327 | Osteoporosis: treatment | ECTS2014

Baseline data of the DEVIDE-study: DEnosumab vs Intravenous Ibandronate: a 2-year retrospective head to head real life study

Amrein Karin , Muschitz Christian , Wagner Doris , Pieber Thomas R , Resch Heinrich , Dimai Hans Peter , Fahrleitner-Pammer Astrid

Introduction: Effective treatment of postmenopausal osteoporosis (PMO) is frequently compromised by poor adherence to short-term (≤1-monthly) medications. Aim of this study is to investigate the effect of parenteral ibandronate (IBN) compared to denosumab in a cohort of IBN pretreated PMO patients.Methods: In a retrospective analysis, a total of 808 women were treated with quarterly 3 mg IBN injections for 27+3 months and were regularly mo...

ba0005p73 | Bone development/growth and fracture repair | ECTS2016

Combination of novel two-photon photopolymerised scaffolds and bioactive elastin-like-recombinamers induce bone regeneration

Kampleitner Carina , Hildebrand Gerhard , Liefeith Klaus , Gonzalez Constancio , Rodriguez-Cabello Jose Carlos , Markus Andrea , Dullin Christian , Alves Frauke , Hoffmann Oskar

Non-healing fractures caused by trauma, disease or tumour resection demand the use of bone grafts to support and stimulate the healing process. We sought to develop and evaluate the effect of a novel bioactive biodegradable biomaterial designed to fill large bone lesions and to improve bone healing. We used two-photon polymerised synthetic polymer scaffolds composed of lactide (LA), caprolactone (CL), and methacrylate (MA) with varying LA: CL ratio and percentage of methacryla...